I just read this e-book, simply because, according to my friend this book is written by some of the ingenious individuals who foresaw and also profited even from the financial collapse. - Sunita
I heard people are using this e-book as a Self-help guide to investing. I recently finished studying it, and never have experimented with any of the strategies; however they all appear to make sense. - Rajiv
A fantastic guide overall. Quite different from almost all other value investing publications because it concentrates on finding unique scenarios that are best to invest in. - Alexis
This particular e-book really opened up my eyes to some fresh opportunities and possibilities that while investing I should be looking for. Once you have read this traditional value investing book you will learn a lot. - Kavita
I really like the writer of this book. It is simple, properly explained, amusing, relevant, and incredibly well planned. This particular e-book is really a holy bible for dealing with unique circumstances in the market. - Saurabh

History of Lupin Laboratories limited [OLDs]

1968

- The Comp. started its pharmaceutical business & engaged as a multi-divisional multi located & multi product company. The company plant at Aurangabad has modern formulation facilities.

1972

- The Comp. was incorporated on 11th July, as a private limited company. It was converted into a public limited Comp. on 30th December 1992. The Comp. was promoted by Desh Bandhu Gupta. The Company origin began when D.B. Gupta bought over the Lupin trade mark from a Comp. called Charak Pharmaceuticals & formed a proprietary concern Lupin Laboratories.

- The Company objects is to manufacture of bulk drugs such as Cephalosporins, Vitamin B-6, Beta Blockers etc. & ethambutol, rifampicin formulations.

- [is] The Comp. undertook to set up a project with a capacity of 18.5 TPA sterile bulk of semi synthetic third generation `Injectable Cephalusporins' on a leasehold land measuing 59.6 acres at Mandideep, a notified backward area in M.P.

- [iis] Also undertook to set up a new plant for manufacture of 50 TPA cefactor at Mandideep. Also intermediable for cefactor was to be manufactured at Ankleshwar, dist. Bharuch, Gujarat.

- [iiis] It was also proposed to set up facilities for manufacture of 75 TPA of ciprofloxacin at Ankleshwar, Bharuch, Gujarat.

1989

- 5,71,840 shares allotted to promoter [of which 2,88,920 shares and 67,960 shares allotted as bonus sharess].

1992

- Ciprofloxacin project was commissioned. It was proposed to expand the capacity 75 TPA. At Mandideep, the second scheme for the manufacture of cepa dorxil & its intermediates was commissioned by February.

- 11,43,680 shares allotted to the promoters in prop. 1:1 in 26.6.1993. Another 162,97,440 bonus shares issued in prop. 19:2 to the promoters.

1993

- During December, the Comp. issued 62,17,500 - 16% secured redeemable partly convertible debentures of Rs.10 each of which 1,59,800 debentures were send for allotment as preferential basis to employees [all were taken ups]. Balance 60,57,700 debentures were issued to the public [all were taken ups].

- Part A of Rs.100 was to be converted into 1 equity share of Rs.10 each for cash at a prem. of Rs.90 per share on date of allotment of debentures. Accordingly 62,17,500 shares were allotted.

- Part B of Rs.200 was to be redeemed at par at Rs.50, Rs.70 & Rs.80 at the end of 3rd, 4th & 5th years respectively from the date of allotment of debentures.

1994

- It was also proposed to build a 500 TPA plant at Mandideep for production of phenyl glycine salts with tieup of NCL, Pune. The project was expected to be completed by June.

- Apart from the new products like AKT-3, AKT-4 & R-Cinex-Z which the company introduced, the oral & injectable Cephalosporins also formed one of biggest segments of pharma market. The company's biotechnology division in collaboration with International Centre for Genetic Engg. in biotechnology will be launched as India first indigenously developed HIV 1/2 diagnostic kit.

- The Comp. set up a plant for manufacturing herbal extracts at Mandideep. Further, the Comp. initiated actions for upgradation/modernisation of formulation facilities for manufacturing Injectable & oral Cephalosporins, matching global standards.

1995

- Apart from streamlining operations or Cefacolor & Injectible Cephalosporins Injectable Cephalosporins capacity has been enhanced. Company has also enhanced plant capacities for oral cephalosporins and their intermediates 7ADCA.

2000

- Lupin Laboratories has agreed an agreement with US-based generics company American Pharmaceutical Partners [APPs] for formulating and marketing its US Food & Drug Administration [FDAs] approved bulk drug cefotaxime.

- Lupin Laboratories is to consider the merger of Lupin Chemicals into the former.

- Lupin Laboratories is considering the sale of its 50 per cent stake in Ceph International Corporation, based in Puerto Rico, to its joint venture partner Mova Pharmaceutical Corporation.

- Lupin Laboratories Ltd., a pharma major, is set to launch its first generic cephalosorins in the main target market of US by end of this financial year.

- Lupin Laboratories has signed a memorandum of understanding with US-based Pathogenesis for research in anti-tuberculosis drugs.

- The Comp. has hired Morgan Stanley as merchant banker & Deloitte, Touche, Haskins and Tohmatsu as valuer for its merger with Lupin Chemicals.